[HTML][HTML] HPV carcinomas in immunocompromised patients
NM Reusser, C Downing, J Guidry… - Journal of clinical medicine, 2015 - mdpi.com
Human papillomavirus (HPV) infection is the most common sexually transmitted disease
worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal …
worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal …
Human papillomavirus–related genital disease in the immunocompromised host: Part II
RH Gormley, CL Kovarik - Journal of the American Academy of …, 2012 - Elsevier
Human papillomavirus is responsible for common condyloma acuminata and a number of
premalignant and malignant anogenital lesions. The immunocompromised population is at …
premalignant and malignant anogenital lesions. The immunocompromised population is at …
Position statement for the diagnosis and management of anogenital warts
C O'Mahony, M Gomberg, M Skerlev… - Journal of the …, 2019 - Wiley Online Library
Background Anogenital warts (AGW) can cause economic burden on healthcare systems
and are associated with emotional, psychological and physical issues. Objective To provide …
and are associated with emotional, psychological and physical issues. Objective To provide …
Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules
WR Lee, SC Shen, SA Al-Suwayeh, HH Yang… - Journal of controlled …, 2011 - Elsevier
The aim of this study was to evaluate the ability of a low-fluence fractional erbium: yttrim-
aluminum-garnet (Er: YAG) laser, with a wavelength of 2940nm, for enhancing and …
aluminum-garnet (Er: YAG) laser, with a wavelength of 2940nm, for enhancing and …
Genital warts and other HPV infections: Established and novel therapies
R Fathi, MM Tsoukas - Clinics in dermatology, 2014 - Elsevier
Wart therapies involve methods of targeted lesion destruction, as well as selective
immunologic modification. While there are several therapeutic options, no treatment has …
immunologic modification. While there are several therapeutic options, no treatment has …
Imiquimod for anogenital warts in non‐immunocompromised adults
CF Grillo‐Ardila, E Angel‐Müller… - Cochrane Database …, 2014 - cochranelibrary.com
Background 30% of people with anogenital warts (AGW) have spontaneous regression of
lesions but there is no way to determine whether a specific lesion will remain. There are a …
lesions but there is no way to determine whether a specific lesion will remain. There are a …
[HTML][HTML] Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice
L Chen, Z Zhou, Y Yang, N Chen, H Xiang - PLoS One, 2017 - journals.plos.org
Background Imiquimod is a Toll-like receptor-7 agonist that regulates immunity and can be
used as an immune adjuvant. Ulcerative colitis has a close correlation with immune …
used as an immune adjuvant. Ulcerative colitis has a close correlation with immune …
Dermatologic manifestations of HPV in HIV-infected individuals
RH Gormley, CL Kovarik - Current HIV/AIDS Reports, 2009 - Springer
Dermatologic human papillomavirus (HPV) infection in HIV patients manifests as both
anogenital and nongenital skin disease. Anogenital HPV-related disease includes benign …
anogenital and nongenital skin disease. Anogenital HPV-related disease includes benign …
[HTML][HTML] A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men
CLA Camargo, W Belda, LJ Fagundes… - Anais Brasileiros de …, 2014 - SciELO Brasil
BACKGROUND: Genital warts are caused by human papillomavirus infection and represent
one of the most common sexually transmitted diseases. Many infections are transient but the …
one of the most common sexually transmitted diseases. Many infections are transient but the …
[HTML][HTML] The toll-like receptor agonist imiquimod is active against prions
N Oumata, PH Nguyen, V Béringue, F Soubigou… - PLoS …, 2013 - journals.plos.org
Using a yeast-based assay, a previously unsuspected antiprion activity was found for
imiquimod (IQ), a potent Toll-like receptor 7 (TLR7) agonist already used for clinical …
imiquimod (IQ), a potent Toll-like receptor 7 (TLR7) agonist already used for clinical …